KRAS and non-small cell lung carcinoma: Unlike in NSCLC, single-agent activity seems to be more limited in KRAS-mutated CRC, lending credence to the hypothesis that other mutations or pathways could be bypassing direct KRAS inhibition and driving tumor growth [106].